Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: a Systematic Review of the Clinical Evidence
Overview
Overview
Affiliations
Affiliations
Soon will be listed here.
References
1.
Savelieva I, Bajpai A, Camm A
. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. Ann Med. 2007; 39(5):371-91.
DOI: 10.1080/07853890701320662.
View
2.
Menke J, Luthje L, Kastrup A, Larsen J
. Thromboembolism in atrial fibrillation. Am J Cardiol. 2010; 105(4):502-10.
DOI: 10.1016/j.amjcard.2009.10.018.
View
3.
Ogilvie I, Newton N, Welner S, Cowell W, Lip G
. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010; 123(7):638-645.e4.
DOI: 10.1016/j.amjmed.2009.11.025.
View
4.
Marinigh R, Lip G, Fiotti N, Giansante C, Lane D
. Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. J Am Coll Cardiol. 2010; 56(11):827-37.
DOI: 10.1016/j.jacc.2010.05.028.
View
5.
Hankey G
. Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?. Curr Opin Neurol. 2009; 23(1):65-72.
DOI: 10.1097/WCO.0b013e328334e67b.
View